Macroencapsulation Device with Anti-inflammatory Membrane Modification Enhances Long-Term Viability and Function of Transplanted β Cells
Source abstract
Abstract
Treating type 1 diabetes (T1D) through β-cell macroencapsulation is a promising long-term solution, but it faces challenges such as immune-mediated fibrosis on the capsule surface, which impairs cell functionality and compromises longevity and effectiveness. This study presents an approach for including an anti-inflammatory molecule on the macroencapsulation device (MED) using initiated chemical vapor deposition for the surface modification of poly(tetrafluoroethylene) (PTFE) membranes. The surface-modified MEDs significantly reduced fibrosis, improved β-cell viability and functionality, and promoted M2 macrophage polarization, which is associated with anti-inflammatory effects. This MED displayed improved glycemic control in a streptozotocin-induced diabetic mouse model for 45 days. The findings underscore the potential of surface-modified MEDs for improving T1D management by mitigating inflammation and enhancing the therapeutic efficacy of β-cell encapsulation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Pancreatic function and diabetes · Diabetes Management and Research · Diabetes and associated disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Bioengineering and Nano-Bioengineering, College of Life Sciences and Bioengineering
Incheon National University
Research Institute of Intelligent Manufacturing & Materials Technology
Korea Institute of Industrial Technology
Brain Science Institute
Korea Institute of Science and Technology
KU-KIST Graduate School of Converging Science and Technology
Korea University
Department of Chemical Engineering
University of Toronto
Division of Materials Science and Engineering
Hanyang University
Division of Bio-Medical Science and Technology, KIST School
Korea University of Science and Technology (UST)
Division of Bioengineering, College of Life Sciences and Bioengineering
Research Center for Bio Materials & Process Development
Funding
Ministry of Health and Welfare · Ministry of Science and ICT, South Korea · Korea Institute of Science and Technology
References (55)
Show source-provided references
1. 10.1016/j.diabres.2021.10908310.1016/j.diabres.2021.109083 ↗
2. 10.1016/s2213-8587(22)00218-210.1016/s2213-8587(22)00218-2 ↗
3. D Ogle, G.; Gregory, G. A.; Maniam, J. Type 1 Diabetes Numbers in Children and Adults; International Diabetes Federation, 2022; pp 1–14.
4. 10.1016/S0140-6736(13)60591-710.1016/S0140-6736(13)60591-7 ↗
5. 10.1136/bmjdrc-2015-00016110.1136/bmjdrc-2015-000161 ↗
6. 10.2337/dc21-175210.2337/dc21-1752 ↗
7. 10.1056/nejmoa220391310.1056/nejmoa2203913 ↗
8. 10.2337/dci19-002810.2337/dci19-0028 ↗
9. 10.1016/s2213-8587(17)30217-610.1016/s2213-8587(17)30217-6 ↗
10. 10.1038/nrendo.2011.3210.1038/nrendo.2011.32 ↗
11. 10.3727/096368915X68893910.3727/096368915X688939 ↗
12. 10.1038/nrd.2016.23210.1038/nrd.2016.232 ↗
13. 10.1016/j.eng.2021.10.02110.1016/j.eng.2021.10.021 ↗
14. 10.2741/419510.2741/4195 ↗
15. 10.1016/S1471-4914(02)02381-X10.1016/S1471-4914(02)02381-X ↗
16. 10.1038/s44222-024-00238-610.1038/s44222-024-00238-6 ↗
17. 10.1016/j.memsci.2022.12111510.1016/j.memsci.2022.121115 ↗
18. 10.1016/j.memsci.2017.12.03210.1016/j.memsci.2017.12.032 ↗
19. 10.1038/s41598-023-38764-910.1038/s41598-023-38764-9 ↗
20. 10.3390/polym1519387410.3390/polym15193874 ↗
21. 10.3390/polym1209207410.3390/polym12092074 ↗
22. 10.1021/cm903156a10.1021/cm903156a ↗
23. 10.1002/adem.20170062210.1002/adem.201700622 ↗
24. 10.1007/s42765-024-00438-010.1007/s42765-024-00438-0 ↗
25. 10.1021/la062422d10.1021/la062422d ↗
26. 10.1002/pola.2348610.1002/pola.23486 ↗
27. 10.1002/pola.2620010.1002/pola.26200 ↗
28. 10.1016/j.eurpolymj.2005.01.02510.1016/j.eurpolymj.2005.01.025 ↗
29. 10.1021/acsami.0c2009610.1021/acsami.0c20096 ↗
30. 10.1039/D3RA03414C10.1039/D3RA03414C ↗
31. 10.3389/fimmu.2022.86998410.3389/fimmu.2022.869984 ↗
32. 10.12703/r/10-7110.12703/r/10-71 ↗
33. 10.1155/2020/834971210.1155/2020/8349712 ↗
34. 10.1016/j.actbio.2018.09.03610.1016/j.actbio.2018.09.036 ↗
35. 10.1038/labinvest.2016.11610.1038/labinvest.2016.116 ↗
36. 10.1101/cshperspect.a02854810.1101/cshperspect.a028548 ↗
37. 10.1073/pnas.81.15.491710.1073/pnas.81.15.4917 ↗
38. 10.1016/j.jiec.2019.02.02110.1016/j.jiec.2019.02.021 ↗
39. 10.1038/s41598-023-32589-210.1038/s41598-023-32589-2 ↗
40. 10.2337/diabetes.50.3.48910.2337/diabetes.50.3.489 ↗
41. 10.1073/pnas.210125811810.1073/pnas.2101258118 ↗
42. 10.4236/oalib.110998810.4236/oalib.1109988 ↗
43. 10.1038/s41598-020-61891-610.1038/s41598-020-61891-6 ↗
44. 10.1016/j.molmet.2022.10144010.1016/j.molmet.2022.101440 ↗
45. 10.1038/s41551-020-0538-510.1038/s41551-020-0538-5 ↗
46. 10.1016/j.actbio.2016.07.00310.1016/j.actbio.2016.07.003 ↗
47. 10.1016/j.actbio.2021.03.03810.1016/j.actbio.2021.03.038 ↗
48. 10.1016/j.biomaterials.2012.02.03410.1016/j.biomaterials.2012.02.034 ↗
49. 10.1126/sciadv.abc320710.1126/sciadv.abc3207 ↗
50. 10.3727/096368912X65734110.3727/096368912X657341 ↗
51. 10.1073/pnas.231170712010.1073/pnas.2311707120 ↗
52. 10.1007/s13770-022-00507-810.1007/s13770-022-00507-8 ↗
53. 10.1900/RDS.2014.11.8410.1900/RDS.2014.11.84 ↗
54. 10.1039/C7NR05446G10.1039/C7NR05446G ↗
55. Abràmoff M. D. · Biophoton. Int. · 2004 · 11 · 36